Glecaprevir + Pibrentasvir bulk supplier for pharma manufacturers

Glecaprevir + Pibrentasvir Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Reference Brands: Mavyret (US); Maviret (EU)

Mavyret/Maviret is a once-daily 3-tablet regimen combining Glecaprevir and Pibrentasvir for pan-genotypic HCV treatment. It offers short 8-week therapy, high cure rates, and is safe for patients with kidney or liver issues.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Glecaprevir + Pibrentasvir? List it or send an offer →

Product Description:

Mavyret (US) / Maviret (EU) is a fixed-dose combination of Glecaprevir 100 mg and Pibrentasvir 40 mg per tablet, approved by the FDA and EMA for the treatment of chronic hepatitis C virus (HCV) infection across genotypes 1–6. This pan-genotypic regimen is taken as three tablets once daily with food. It offers one of the shortest HCV treatments—just 8 weeks for most patients. Mavyret is highly effective (SVR >95%) and suitable for use in patients with renal impairment and compensated cirrhosis. Its ribavirin-free formulation improves tolerability, making it a convenient, high-efficacy option for diverse patient populations.

Glecaprevir + Pibrentasvir — third party manufacturing & bulk supply

Glecaprevir + Pibrentasvir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Glecaprevir + Pibrentasvir is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Glecaprevir + Pibrentasvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Glecaprevir + Pibrentasvir →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Glecaprevir and Pibrentasvir are used together for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes (1–6). This combination is highly effective and is used in both treatment-naïve and treatment-experienced patients, with or without cirrhosis.

This fixed-dose combination contains glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor. Together, they block viral replication at two different stages of the HCV life cycle, leading to sustained virologic response.

The globally recognized trade name for this combination is Mavyret (also known as Maviret in some regions).

Mavyret/Maviret is manufactured by AbbVie.

The generic name of the product is glecaprevir and pibrentasvir.

The common brand name is Mavyret (or Maviret depending on the market).

Glecaprevir + Pibrentasvir (Mavyret/Maviret) is manufactured by AbbVie in its approved global pharmaceutical production facilities located in the United States and Europe. Generic versions, where permitted, are produced by licensed manufacturers in select countries.